Want to join the conversation?
$VRTX has exclusively licensed VX-210 to treat acute spinal cord injury from BioAxone BioSciences. VX-210 is designed to inhibit protein known as Rho that blocks neural regeneration after injury. $VRTX will start Phase 2b/3 clinical trial in 1H16 to evaluate efficacy and safety of VX-210 in patients with certain acute cervical spinal cord injuries.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.